 Connection
Enrique Alvarez to Demyelinating Diseases
This is a "connection" page, showing publications Enrique Alvarez has written about Demyelinating Diseases.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.283 |
|
|
|
-
Longbrake EE, Hua LH, Mowry EM, Gauthier SA, Alvarez E, Cross AH, Pei J, Priest J, Raposo C, Hafler DA, Winger RC. The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Mult Scler Relat Disord. 2022 Dec; 68:104143.
Score: 0.189
-
Gross PS, Dur?n-Laforet V, Ho LT, Melchor GS, Zia S, Manavi Z, Barclay WE, Lee SH, Shults N, Selva S, Alvarez E, Plemel JR, Fu MM, Schafer DP, Huang JK. Senescent-like microglia limit remyelination through the senescence associated secretory phenotype. Nat Commun. 2025 Mar 07; 16(1):2283.
Score: 0.056
-
Honce JM, Nair KV, Sillau S, Valdez B, Miravalle A, Alvarez E, Schreiner T, Corboy JR, Vollmer TL. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019 02 12; 92(7):e723-e732.
Score: 0.037
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|